Diamyd Medical
Diamyd Medical AB (OMX: DIAM B, OTCQX: DMYDY) is a Swedish medical research company, listed on the Stockholm Stock Exchange. Diamyd's research utilises two different platform technologies. One is based on the GAD65 molecule, which is used in a vaccine that has proven effective in delaying the destruction of beta cells associated with type 1 diabetes, the other on a system to deliver substances directly to nerve cells. The use of GAD65 for therapeutic purposes is licensed from the University of California, Los Angeles. In March, 2008 Diamyd's application for a phase III trial in the United States was approved by the U.S. Food and Drug Administration. The company will perform a parallel phase III trial in Europe.
Read more about Diamyd Medical: Product Portfolio, Licences, Investments, Ongoing Trials, Finished Trials
Famous quotes containing the word medical:
“There may perhaps be a new generation of doctors horrified by lacerations, infections, women who have douched with kitchen cleanser. What an irony it would be if fanatics continued to kill and yet it was the apathy and silence of the medical profession that most wounded the ability to provide what is, after all, a medical procedure.”
—Anna Quindlen (b. 1952)